2.05
+0.08(+4.06%)
Currency In USD
Address
Building F
Iselin, NJ 08852
United States of America
Phone
609 619 3990
Sector
Healthcare
Industry
Biotechnology
Employees
23
First IPO Date
June 14, 2016
| Name | Title | Pay | Year Born |
| Mr. Lawrence A. Kenyon CPA | EVice President, Chief Financial Officer, Interim Chief Executive Officer, Treasurer, Secretary & Director | 476,170 | 1966 |
| Mr. Jeffrey Evanson | Chief Commercial Officer | 451,170 | 1969 |
| Dr. Surendra Sharma M.D. | Senior Vice President of Medical Affairs | 0 | N/A |
| Dr. Jennifer M. Kissner Ph.D. | Senior Vice President of Clinical Development & Regulatory Affairs | 0 | N/A |
| Mr. Joel Prieve | Senior Vice President of Licensing and M&A | 0 | N/A |
| Mr. Jedd Comiskey | Senior Vice President - Head of Europe | 0 | N/A |
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.